Sponsor study identifier
interventional
185
1 country
1
Study Start
October 2009
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
October 2014
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
October 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
A prospective, randomized trial of autologous bone marrow transplantation compared with allogeneic bone marrow transplantation in multiple myeloma.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 2009
Date type not reportedThis date has not been verified as actual or estimated.
October 17, 2009
Actual (reported)October 20, 2009
Actual (reported)October 2014
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
October 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Overall Survival and Progressive Free Survival in both two arms
1 year
Overall Survival and Progressive Free Survival in both two arms
3 year
Treatment Related Mortality (TRM) in both two arms
3 year
Acute and Chronic GVHD in Allogeneic arm
3 year
Autologous transplantation: * Endoxan (for mobilization) Dose: 2.5 g/m2 IV Time: -11 Duration: 1 day * G-CSF (Neupogen) Dose: 0.5 micg/kg subcutaneous Time: -6 to -3 Duration: 4 days * Melphalan Dose: 100 mg/m2 IV Time: -2 and -1 Duration: 2 days
Hematology-Oncology & SCT Research Center
Tehran, Tehran Province, Iran
Ardeshir Ghavamzadeh, MD
Hematology-Oncology and SCT Research Center
First Submitted
October 17, 2009
First Posted
October 20, 2009
Study Start
October 2009
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
October 2014
Estimated (date passed)Hematopoietic Stem Cell Transplantation in Myeloma
Allogeneic * Melphalan Dose: 70 mg/m2 IV Time: Duration: 2 days * Fludarabine Dose: 30 mg/m2 IV Time: Duration: 5 days
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
October 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
June 4, 2012
Record last verified: 2012-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: